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Abstract
Introduction We develop a multiplex quantitative real-
time PCR for synchronized analysis of mitochondrial DNA
(mtDNA) and nuclear DNA (nDNA) to investigate relative
mtDNA abundance in paired normal and cancerous breast
tissues.
Materials and methods The amounts of nDNA and
mtDNA in 102 tissue samples were quantiWed for both
glyceraldehype-3-phosphodehydrogenase (GAPDH) gene
and mtDNA encoded ATPase (MTATP) 8 gene. The aver-
age threshold cycle (Ct) number values of the nDNA and
mtDNA were used to calculate relative mtDNA content in
breast tissues.
Results The median delta Ct (Ct) and the median
mtDNA content for normal and cancerous breast tissues
were 6.73 and 2.54, as well as 106.50 and 5.80 (P = 0.000,
respectively). The mtDNA content was decreased in 82%
of cancerous breast tissues compared with the normal ones.
The changes were associated with hormone receptor status.
Conclusion Our Wnding suggests that decreased mtDNA
content in breast cancer may have diagnostic and prognos-
tic value for the disease.
Keywords Quantitative alteration · Mitochondrial DNA · 
Breast cancer · Breast tissue
Introduction
Human cells have a nuclear genome and additional cyto-
plasmic genomes that are compartmentalised in the mito-
chondria. In comparison to nuclear genomic DNA,
mitochondrial DNA (mtDNA) reveals high mutation rates
caused by constant exposure to mutagenic oxygen radicals
and lacks the protective mechanisms of DNA repair. These
properties of mtDNA suggest their potential importance in
ageing, apoptosis and especially carcinogenesis (Zhang and
Qi 2008; Zhang et al. 2008).
Qualitative aberrations of mtDNA, such as mutations,
have been found in solid tumours, such as colon, stomach,
liver, kidney, bladder, prostate, skin and lung cancer (Copeland
et al. 2002; Penta et al. 2001), and in haematological malig-
nancies, such as leukaemia and lymphoma (Fontenay et al.
2006). Quantitative aberrations of mtDNA have been
observed in various sample types from patients with
cancers (Mambo et al. 2005). While increased mtDNA
content has been found in prostate (Mizumachi et al.
2008a), head and neck (Kim et al. 2004), endometrial
adenocarcinoma (Wang et al. 2005), etc., reduced mtDNA
content in renal (Meierhofer et al. 2004) and liver cancers
(Yin et al. 2004) has been reported.
Because of these mutations and the quantitative aberra-
tions involved in the development of human cancers,
mtDNA may have promising clinical applications for can-
cers (Jiang et al. 2005; Jain 2007). Decreased mitochondrial
DNA copy number is correlated with tumour progression
and prognosis in Chinese breast cancer patients (Yu et al.
2007). Increased mtDNA content in saliva is associated
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levels of cell free circulating mtDNA in prostate cancer
patients with poor prognosis could be a valuable predictor
of prognosis (Ellinger et al. 2008; Mehra et al. 2007). Fur-
thermore, mtDNA aberrations play important roles in
response to cancer therapy, for example, causing resistance
to therapeutic agents (Mizumachi et al. 2008b; Chen et al.
2007).
In the present study, we developed a simple and accurate
multiplex real-time PCR method for synchronised quantiWca-
tion of nuclear DNA (nDNA) and mtDNA in paired adjacent
normal and cancerous breast tissue samples from 51 patients
with breast cancer. The content of MTATP8 gene on mtDNA
in the cancerous tissues was compared with that in normal
tissues from the same patients. We analysed the correlation
between the content of mtDNA in tissues and the traditional
pathological parameters and clinical predictive markers.
Materials and methods
Samples
The study was approved by the local institutional review
board. ParaYn-embedded sections from adjacent normal
and cancerous breast tissue samples were examined by two
experienced pathologists. Breast cancer characteristics, the
histological grading; hormone receptor status and biomark-
ers from the breast cancer patients are listed in Table 1.
DNA was extracted from three to Wve sections of each
10 m thick paraYn-embedded sample (around 0.01–
0.02 g of tissue) using a High Pure PCR Template Prepara-
tion Kit (Roche Diagnostics, Germany) and eluted into
150 l of elution buVer. The eluted DNA was stored at
¡20°C until further use.
Real-time PCR
The amounts of nDNA and mtDNA were quantiWed by mul-
tiplex TaqMan real-time PCR for both GAPDH gene of
nDNA and MTATP 8 gene of mtDNA starting at locus 8446.
The GAPDH and MTATP 8 primer and probe sequences are
shown as follows: GAPDH (forward):5 CCC CAC ACA
CAT GCA CTT ACC3; (reverse): 5CCT AGT CCC AGG
GCT TTG ATT 3; probe 5 (MGB) TAG GAA GGA CAG
GCA AC (VIC) 3. MTATP 8 (forward): 5 AAT ATT AAA
CAC AAA CTA CCA CCT ACC 3; (reverse): 5 TGG TTC
TCA GGG TTT GTT ATA 3; probe: 5 (MGB) CCT CAC
CAA AGC CCA TA (FAM) 3.
The PCR was performed using the ABI PRISM 7000
Sequence Detection System (Applied Biosystems, ABI). A
total of 2.5 l of DNA were used as template for the PCR
analysis. The real-time PCR were carried out in 25 l of
total reaction volume using a 2 min incubation at 50°C, fol-
lowed by an initial denaturation step at 95°C for 10 min and
40 cycles of 1 min at 60°C and 15 s at 95°C.
To determine the quantities of mtDNA and nDNA pres-
ent in tissue samples, standard dilution curves using HPLC-
puriWed single-stranded synthetic DNA oligonucleotides
(Microsynth) specifying a 79-bp MTATP 8 gene amplicon
and a 97-bp GAPDH amplicon with concentration ranging
from 5 £ 107 copies to 5 £ 102 copies, were used. We
examined the ampliWcation eYciency for both GAPDH and
MTATP 8 on experimental serial dilutions. The ampliWca-
tions of mtDNA and nDNA on serial dilutions showed a
good correlation with comparable eYciencies. A threshold
cycle (Ct) reXects the cycle number at which a Xuorescence
signal within a reaction crosses a threshold. In our study,
the average threshold cycle number (Ct) values of the
nDNA and mtDNA were obtained from each case. The
content of mtDNA was calculated using the delta Ct (Ct)
of average Ct of mtDNA and nDNA (Ct = CtnDNA ¡
CtmtDNA) in the same well as an exponent of 2 (2Ct).
Statistical analysis
The data were analysed using SPSS software (Statistical
Software Package for Windows v. 15.0). Content of
mtDNA is given as the median, the range and the fold
diVerence. Wilcoxon signed ranks test was used to compare
the diVerences between ranks of each paired samples. The
Mann–Whitney U test and Kruskal–Wallis test was used to
compare the content of mtDNA in normal adjacent normal
tissues and cancerous tissues. The Spearman rank test was
applied to analyse the relationship of mtDNA content
between normal tissues and cancerous tissues.
Results
Co-extraction of mtDNA and nDNA from the paired breast 
tissue samples
Nuclear DNA and mtDNA were co-extracted from the par-
aYn-embedded sections. The average Ct values for
GAPDH sequence, representing total nDNA, ranged from
24.42 to 37.08 in cancerous tissues and from 25.19 to 38.38
in normal tissues, respectively. The average Ct values for
MTATP 8 gene sequence, representing total mtDNA,
ranged from 18.48 to 32.54 in cancerous tissues and from
19.28 to 33.42 in normal tissues, respectively. The average
Ct values of mtDNA were less than those of nDNA in all
cases, represented higher amounts of mtDNA than those of
nDNA in the breast tissues. While the average Ct values of
GAPDH ampliWcation in the normal tissues are correlated
with those of MTATP8 gene ampliWcation (Spearman rank123
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was observed in cancerous tissues (P > 0.05, r = 0. 261)
(Fig. 1b), suggesting an alteration of the relationship
between nDNA and mtDNA in cancerous tissues.
Content of mtDNA in paired normal and cancerous breast 
tissues
The Ct values between GAPDH ampliWcation and
MTATP 8 gene ampliWcation show a 6.73 cycle diVerence
in normal tissues and 2.54 cycle diVerence in cancerous tis-
sues. The Ct values between normal and cancerous tissues
shows a 4.2 cycle diVerence (Ct) (Mann–Whitney U test
P < 0.001) (Table 2). We calculated the content of mtDNA
in the tissues using a formula of 2Ct. The content of
mtDNA in cancerous tissues is signiWcantly lower than that
in normal tissues (Mann–Whitney U test P < 0.001)
(Fig. 2). Out of 51 paired samples, 42 pairs show mtDNA
in normal tissues > mtDNA in cancerous tissues (Wilcoxon
signed ranks test P < 0.001).
Relationship between decreased content of mtDNA 
and other established prognostic factors
In this study, associations between the content of mtDNA
in breast tissues and traditional clinical parameters, such as
age, tumour type, tumour size, lymph node involvement,
extent of metastasis, stage, histological grading, receptor
status and pathological biomarkers (HER-2/neu and PS2),
were analysed (Table 1).
Table 1 Patients data as well as 
relationships between decreased 
content of mtDNA in cancerous 
tissues and clinical factors
Variables Group (cases) mtDNA content P value
Age <50 (32) 195.36 (6.70–2,460.95) 0.596*
¸50 (19) 23.48 (6.43–284.05)
Histological type Ductal (41) 53.82 (1.35–9,877.98) 0.337*
Lobular (10) 201.39 (7.31–823.14)
Primary tumour T1 (23) 149.09 (6.43–749.61) 0.824**
T2 (15) 23.48 (6.70–861.08)
T3 (9) 2382.54 (2,304.12–2,460.95)
Lymph node involvement Positive (41) 149.09 (6.43–2,460.95) 0.201*
Negative (9) 57.82 (9.48–106.15)
Distant metastasis M0 (40) 137.44 (6.70–2,460.95) 0.585*
M1 (10) 53.82 (6.43–584.07)
Stage I (5) 57.82(9.48–106.15) 0.140**
II (27) 137.44 (6.70–861.08)
III (6) 2382.54 (2,304.12–2,460.95)
IV (9) 53.82 (6.43–584.07)
Histological grading G1 (8) 397.97 (9.48–2,460.95) 0.696**
G2 (19) 195.36 (6.43–861.08)
G3 (15) 34.22 (7.31–225.97)
Nuclear grading 1 (3) 57.82 (9.48–106.15) 0.418**
2 (14) 195.36 (9.99–2,304.12)
3 (16) 137.44 (6.43–2,460.95)
ER Positive (14) 12.46 (1.18–69,272.73) 0.613*
Negative (18) 6.57 (1.18–8,451.55)
PR Positive (18) 20.83 (1.18–69,272.73) 0.037*
Negative (14) 3.77 (1.18–394.81)
Her2 Positive (15) 53.82 (6.70–2,460.95)
Negative (17) 210.67 (6.43–2,304.12)
P53 Positive (3) 1205.14 (106.15–2,304.12) 0.153*
Negative (29) 125.80 (6.43–2,460.95)
PS2 Positive (11) 106.15 (6.43–2,304.12) 0.699*
Negative (20) 137.44 (6.70–2,460.95)
Ki62 Positive (0)
Negative (31) 125.80 (6.43–2,460.95)
ER Oestrogen receptor, 
PR progesterone receptor
* Mann–Whitney U test, 
** Kruskal–Wallis test123
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associated with age (¸50 vs. <50), tumour type (ductal vs.
lobular), tumour size (T1, T2, T3), lymph node involve-
ment (N0 and N1), extent of metastasis (M0 vs. M1), stage,
histological grading (I, II, III), HER-2/neu ampliWcations
and PS2 detections (Table 1). However, while we found
signiWcantly decreased mtDNA content in normal tissues of
an oestrogen receptor (ER) negative detection compared
with that of an ER positive detection (mtDNA in normal
tissues 89.81 vs. 756.46, P = 0.041; mtDNA in cancerous
tissues 6.57 vs. 12.46, P = 0.613) (Fig. 3a), a signiWcantly
decreased content of mtDNA in both normal and cancerous
tissues of a progesterone receptor (PR) negative detection
compared with that of PR positive tissues was observed
(mtDNA in normal tissues 37.67 vs. 434.06, P = 0.016;
mtDNA in cancerous tissues 3.77 vs. 20.83, P = 0.037)
(Fig. 3b).
Discussion
In this study, we found that mtDNA content of MTATP 8
gene for encoding ATP synthase was decreased in 42 of 51
(82%) cancerous breast tissues compared to their normal
breast tissues collected from same individuals (Table 2).
Fig. 1 a mtDNA ampliWcations are correlated with nDNA ampliWca-
tions in normal tissues (P = 0.000, r = 0.63); b mtDNA ampliWcations
are not correlated with nDNA ampliWcations in cancerous tissues
(P = 0.065, r = 0.261)
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Table 2 Comparison of mtDNA content in normal and cancerous breast tissues
* Mann–Whitney U test; ** Spearman Rank test; *** Wilcoxon Signed Ranks test
Normal (N) 51 Cancerous (C) 51 Fold SigniWcances/
correlation (P value)
CT = CtnDNA – CtmtDNA 6.73 2.54 CT: 0.000*
0.43–13.27 0.23–16.08 6.73–2.54 = 4.2
Content = 2CT 106.20 5.80 Fold 0.000*
1.30–9877.90 1.20–69272.70 106.20/5.80 = 18.3 0.242** (C:N)
N > C or C > N 42 9 0.000***
Correlation (CtnDNA:CtmtDNA) **P = 0.000 **P = 0.065
r = 0.63 r = 0.26
Fig. 2 mtDNA content in paired adjacent normal and cancerous breast
tissues
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regions on mtDNA, Yu et al. (2007) (on D-loop), Mambo
et al. (2005) (on Co I region) and Tseng et al. (2006) (on
ND1 gene) found the similar phenomenon. This suggests
that, as it has been reported for other cancer types, quantita-
tive alterations of mtDNA may be a potential biomarker for
breast cancer. Both decrease and increase of mtDNA con-
tent in cancers have been shown in many studies, varying
with tissue type or origin of tumours, because of diVerent
patterns of mitochondrial transcripts coding for proteins
involved in oxidative phosphorylation (Lebrecht et al.
2005; Masuyama et al. 2005).
Decrease of mtDNA has been observed in renal cancer
(Meierhofer et al. 2004) and hepatocellular carcinoma (Yin
et al. 2004). However, the pathogenesis of mtDNA
decrease in cancers remains unclear. It was hypothesised
that mitochondrial respiratory dysfunction and damage of
mtDNA, such as mutation, deletion or depletion, in carci-
nogenesis may course the quantitative alterations (Ye et al.
2008). Those alterations of mtDNA could correlate with
increased risk (Mosquera-Miguel et al. 2008; Bai et al.
2007) and increased invasiveness of cancer (Simonnet et al.
2002). Decreased mtDNA content can cause decreased oxi-
dative phosphorylation capacity that could increase cancer
cell growth under hypoxic conditions during cancer devel-
opment and cancer progression (Rossignol et al. 2004).
Depletion of mtDNA can also lead to cells resistant to a
certain apoptosis pathway during cancer development (Hig-
uchi 2007).
In our study, mtDNA content was signiWcantly decreased
in cancerous breast tissues. However, high copy numbers of
mtDNA per cell compared to those of nDNA (from 22.535 to
26.73 is from 5.8- to 106.2-fold higher in our study) may still
increase the sensitivity of testing mtDNA alterations, thus
having more promising clinical applications in cancers.
Using QuantiTest SYBR Green PCR, Yu et al. (2007)
found that, on a 59 case study, mtDNA copy number alter-
ation is correlated with tumour progression and prognosis
in Chinese breast cancer patients. They showed that the
reduced copy number in mtDNA was associated with an
older onset age (¸50 years old) and a higher histological
grade. We compared the decrease in mtDNA content with
other traditional clinical parameters, such as age, tumour
size, lymph node involvement, extent of metastasis, and
predictive markers, such as histological grades, HER-2/neu
ampliWcation and PS2 detection. No relationship was found
between the decrease and those parameters. It was likewise
shown by Mambo et al. (2005) that changes in mtDNA
content in breast cancer did not correlate with tumour grade
and metastasis, suggesting that these alterations may occur
in the early stages of tumorigenesis.
However, in our study, we did Wnd associations between
mtDNA content and hormone receptor status. MtDNA con-
tent is signiWcantly higher in ER positive normal breast tis-
sues than that in ER negatives, suggesting that ER status in
normal breast tissue may play a part in mtDNA function.
Chen et al. (2004) observed that ER is present in mitochon-
dria of human MCF7 cells, implying that oestrogens can
have an eVect on mitochondrial via ER in regulation of
mitochondrial respiratory chain structure and function
(Chen et al. 2005; Yager and Chen 2007). A similar phe-
nomenon was not shown in the cancerous tissues. We pre-
sume that mtDNA dependent ER action may be altered
during cancer development in vivo.
In our study, we also observed that changes in mtDNA
content are associated with PR in both normal and cancer-
ous tissues (mtDNA in PR positive > that in PR negative).
We assume that the changes may be tissue speciWc rather
than tumour speciWc. Several studies showed that mito-
chondria respiration varies during the menstrual cycle and
Fig. 3 a mtDNA content in ER positive and ER negative normal and
cancerous tissues; b mtDNA content in PR positive and PR negative
normal and cancerous tissues. ER+ estrogen receptor positive, ER¡
estrogen receptor negative, N normal tissues, Ccancerous tissues, PR+
progesterone receptor positive, PR¡ progesterone receptor negative
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988 J Cancer Res Clin Oncol (2009) 135:983–989is associated with pregnancy (BuVenstein et al. 1995; Webb
1986). Mitochondria respiration increases during the pro-
gesterone-dominant lucteal phase.
In conclusion, our data suggest that using a robust Taq-
man real-time PCR, the content of mtDNA in breast tissues
can be easily quantiWed. MtDNA content in breast cancer
tissues decreased dramatically, and the changes are not
associated with most traditional prognostic parameters.
Many studies in vitro, using animal models and cell culture
models, showed that reduced mtDNA content could lead to
cells resistant to apoptosis, favour cancer cell growth,
increase invasiveness and contribute to progression and
metastasis of cancer cells. Therefore, decrease of mtDNA
content in breast cancer may have diagnostic and prognos-
tic value. In this study, we also found hormone receptor
related changes in mtDNA content, which may assist us in
understanding the biology of mtDNA in gender and age
manner.
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